NAII

CARLSBAD, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $4.3 million, or $0.72 per diluted share, on net sales of $35.5 million for the third quarter of fiscal year 2026 compared to a net loss of $2.2 million, or $0.37 per diluted share, in the third quarter of the prior fiscal year. Net sales during the three months ended March 31, 2026, increased $6.7 million, or 23%, to $35.5 million as compared to $28.8 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales increased 25% to $33.8 million, primarily due to increased orders from one of our largest customers and shipments to new customers, partially offset by a net decrease in shipments to other existing customers. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue were relatively flat at $1.7 million during the third quarter of fiscal year 2026 and fiscal year 2025. Our net loss for the nine months ended March 31, 2026, was $7.2 million, or $1.19 per diluted share, compared to a net loss of $6.4 million, or $1.07 per diluted share, for the nine months ended March 31, 2025. Net sales during the nine months ended March 31, 2026, increased $12.0 million, or 13%, to $108.0 million as compared to $96.0 million recorded in the comparable prior year period. During the nine months ended March 31, 2026, private-label contract manufacturing sales increased 14% to $102.7 million, as compared to $90.0 million in the comparable prior period. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 11% to $5.3 million during the first nine months of fiscal 2026, as compared to $6.0 million for the first nine months of fiscal 2025. While we grew our net sales during the three and nine months ended March 31, 2026, as compared to the prior year periods, we experienced a loss from operations due primarily to underutilization of our factory capacities. The growth in net sales is primarily related to increased new and existing private label contract manufacturing customer sales that drove improved factory utilization, partially offset by a decrease in patent and trademark licensing net sales. While we anticipate our sales revenue for the f...

CARLSBAD, Calif. (AP) — CARLSBAD, Calif. (AP) — Natural Alternatives International Inc. (NAII) on Monday reported a loss of $4.3 million in its fiscal third quarter. On a per-share basis, the Carlsbad, California-based company said it had a loss of 72 cents. The nutritional supplements manufacturer posted revenue of $35.5 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NAII at https://www.zacks.com/ap/NAII

CARLSBAD, Calif. (AP) — CARLSBAD, Calif. (AP) — Natural Alternatives International Inc. (NAII) on Friday reported a loss of $2.6 million in its fiscal second quarter. On a per-share basis, the Carlsbad, California-based company said it had a loss of 42 cents. The nutritional supplements manufacturer posted revenue of $34.8 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NAII at https://www.zacks.com/ap/NAII

CARLSBAD, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.6 million, or $0.42 per diluted share, on net sales of $34.8 million for the second quarter of fiscal year 2026 compared to a net loss of $2.2 million, or $0.37 per diluted share, in the second quarter of the prior fiscal year. Net sales during the three months ended December 31, 2025, increased $0.7 million, or 2%, to $34.8 million as compared to $34.1 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales increased 2% to $32.8 million. Private-label contract manufacturing sales increased primarily due to increased orders from several of our existing customers and shipments to new customers, partially offset by decreased shipments to other existing customers. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue increased 13% to $2.0 million during the second quarter of fiscal year 2026, as compared to $1.8 million for the second quarter of fiscal year 2025. The increase was primarily due to increased raw material orders from existing customers partially offset by a decrease in royalty and licensing revenue. Our net loss for the six months ended December 31, 2025, was $2.8 million, or $0.47 per diluted share, compared to a net loss of $4.2 million, or $0.70 per diluted share, for the six months ended December 31, 2024. Net sales during the six months ended December 31, 2025, increased $5.3 million, or 8%, to $72.5 million as compared to $67.2 million recorded in the comparable prior year period. During the six months ended December 31, 2025, private-label contract manufacturing sales increased 9% to $68.9 million, as compared to $62.9 million in the comparable prior period. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 15% to $3.7 million during the first six months of fiscal 2026, as compared to $4.3 million for the first six months of fiscal 2025. While we grew our net sales, expanded our gross margins and reduced selling, general and administrative costs during the three and six months ended December 31, 2025, we experienced a loss from operations during the first six months of fiscal 2026 primarily d...

CARLSBAD, Calif. (AP) — CARLSBAD, Calif. (AP) — Natural Alternatives International Inc. (NAII) on Wednesday reported a loss of $291,000 in its fiscal first quarter. On a per-share basis, the Carlsbad, California-based company said it had a loss of 5 cents. The nutritional supplements manufacturer posted revenue of $37.7 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NAII at https://www.zacks.com/ap/NAII

CARLSBAD, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $0.3 million, or $0.05 per diluted share, on net sales of $37.7 million for the first quarter of fiscal year 2026 compared to a net loss of $2.0 million, or $0.33 per diluted share, in the first quarter of the prior fiscal year. Net sales during the three months ended September 30, 2025, increased $4.6 million, or 13.8%, to $37.7 million as compared to $33.2 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales increased $5.4 million, a 17.7% increase from the comparable quarter last year. Private-label contract manufacturing sales increased primarily due to increased orders from several of our existing customers and shipments to new customers. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 33.9% to $1.7 million during the first quarter of fiscal year 2026, as compared to $2.5 million for the first quarter of fiscal year 2025. The decrease in patent and trademark licensing revenue during the first quarter of fiscal 2026 was primarily due to decreased raw material orders from existing customers, partially offset by sales of our new TriBsyn™ product and increased royalty and licensing revenue. We generated income from operations during the first quarter of fiscal 2026 as compared to a loss from operations during the first quarter of fiscal 2025. The improvement in our results from operations was primarily driven by increased sales and gross profit while selling, general, and administrative expenses remained relatively flat. The improvement in gross profit is primarily related to improved utilization of our factory capacities, increased new and existing customer sales, and lower volume rebates. We continue to anticipate that we will experience a net loss in the first half of fiscal 2026, net income in the second half of fiscal 2026, and net income for the full fiscal 2026 year. As of September 30, 2025, we had cash of $7.7 million and working capital of $31.2 million compared to $12.3 million and $30.5 million respectively, as of June 30, 2025. As of September 30, 2025, we had $10.0 million of borrowing capacity on our credit fac...

CARLSBAD, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $7.2 million, or ($1.20) per diluted share, on net sales of $33.9 million for the fourth quarter of fiscal year 2025 compared to a net loss of $1.9 million, or ($0.32) per diluted share, in the fourth quarter of the prior fiscal year. Our net loss for the fourth quarter of fiscal 2025 included non-recurring non-cash charges of $1.4 million related to the settlement of a litigation matter and a $4.8 million valuation allowance against our net deferred tax assets. Excluding these charges, our net loss for the fourth quarter of fiscal 2025 would have been $1.0 million. Net sales during the three months ended June 30, 2025, increased $4.4 million, or 15%, to $33.9 million compared to $29.5 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales increased 15% to $31.8 million. Private-label contract manufacturing sales increased primarily due to increased orders from several of our existing customers and orders from new customers, partially offset by reduced orders from one of our larger customers. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue increased 14% to $2.1 million during the fourth quarter of fiscal year 2025, as compared to $1.8 million for the fourth quarter of fiscal year 2024. The increase in CarnoSyn® beta-alanine royalty, licensing, and raw material sales revenue during the fourth quarter of fiscal 2025 was primarily due to increased raw material sales to existing customers and royalty income. Our net loss for fiscal year 2025 was $13.6 million, or ($2.28) per diluted share, compared to a net loss of $7.2 million, or ($1.23) per diluted share, for fiscal year 2024. Our net loss for fiscal 2025 included non-recurring non-cash charges of $1.4 million related to the settlement of a litigation matter and a $4.8 million valuation allowance against our net deferred tax assets. Excluding these charges, our net loss for fiscal 2025 would have been $7.4 million. Net sales during the year ended June 30, 2025, increased $16.1 million, or 14%, to $129.9 million as compared to $113.8 million recorded in the comparable prior year period. Du...

Revenue: US$28.8m (up 14% from 3Q 2024). Net loss: US$2.19m (loss widened by 39% from 3Q 2024). US$0.37 loss per share (further deteriorated from US$0.27 loss in 3Q 2024). We've discovered 2 warning signs about Natural Alternatives International. View them for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Natural Alternatives International shares are up 4.1% from a week ago. Before you take the next step you should know about the 2 warning signs for Natural Alternatives International (1 is a bit concerning!) that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

CARLSBAD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.2 million, or $0.37 per diluted share, on net sales of $28.8 million for the third quarter of fiscal year 2025 compared to a net loss of $1.6 million, or $0.27 per diluted share, in the third quarter of the prior fiscal year. Net sales during the three months ended March 31, 2025, increased $3.6 million, or 14%, to $28.8 million as compared to $25.1 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales increased 20% to $27.1 million, primarily due to increased orders from several of our larger customers and shipments to new customers. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 36% to $1.7 million during the third quarter of fiscal year 2025, as compared to $2.7 million for the third quarter of fiscal year 2024, primarily due to a decrease in orders from existing customers. Our net loss for the nine months ended March 31, 2025, was $6.4 million, or $1.07 per diluted share, compared to a net loss of $5.3 million, or $0.91 per diluted share, for the nine months ended March 31, 2024. Net sales during the nine months ended March 31, 2025, increased $11.7 million, or 14%, to $96.0 million as compared to $84.3 million recorded in the comparable prior year period. During the nine months ended March 31, 2025, private-label contract manufacturing sales increased 16% to $90.0 million, as compared to $77.7 million in the comparable prior period. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 9% to $6.0 million during the first nine months of fiscal 2025, as compared to $6.6 million for the first nine months of fiscal 2024. While we grew our net sales during the three and nine months ended March 31, 2025 as compared to the prior year periods, we continued to experience a loss from operations due primarily to the underutilization of our factory capacities, lower beta-alanine royalty and licensing revenue, and increased operating expenses primarily related to legal costs, selling, general and administrative, salaries and wages. Manufacturing costs were also negatively impacted by increased labor, for...